India Backs Price Regulator In Ranbaxy Antibiotic Dispute
This article was originally published in PharmAsia News
Executive Summary
India's government has backed its drug-price regulator's decision to fix the price of Ranbaxy Laboratories' Roscillin (ampicillin trihydrate IP) antibiotic. The action by the Chemicals and Fertilisers Ministry, which was ordered by the Delhi High Court to review Ranbaxy's objection, is considered a setback for Indian drug makers. The ministry's decision is seen as an indication the government has no intention of interfering with its National Pharmaceutical Pricing Authority. (Click here for more